The Oncology Institute, Inc. provides value-based community oncology care through clinics and affiliate locations across multiple states. Company updates commonly cover quarterly results, payor and Medicare Advantage contract activity, capitated care models, specialty pharmacy performance, clinical trials, transfusions, and participation in CMS oncology care programs.
News also addresses clinical pathways, legal and compliance leadership, and healthcare investor conference participation. The issuer's public securities include common stock under TOI and redeemable warrants under TOIIW.
Starling Oncology (NASDAQ: STLN) will release its third quarter 2026 financial results on November 5, 2026, followed by a conference call. The call begins at 5:00 p.m. Eastern Time and will also be webcast through the company’s Investor Relations website. A telephone replay will be available approximately three hours after the call until November 19, 2026, at 11:59 p.m. Eastern Time.
Starling Oncology (NASDAQ: STLN) highlighted recent industry conference participation by its physician leaders and previewed upcoming appearances focused on community oncology.
Jeffrey Langsam participated in Deutsche Bank’s Healthcare Summit on September 17, 2026, and Yale D. Podnos joined the Patient-Centered Oncology Care Conference on September 25. Podnos will join panels on cancer care economics and clinical trial access at the AVBCC Summit on October 8, 2026. He will also present on integrating behavioral health into community oncology at the APG Fall Conference on November 19, 2026.
Starling Oncology (NASDAQ: STLN) announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the Wells Fargo Healthcare Conference in Boston on Tuesday, September 8, 2026. Their appearance will include a fireside chat scheduled from 4:30–5:05 p.m. ET, with a webcast available via the Investor Relations section of the company’s website.
Starling Oncology (NASDAQ: STLN) launched Starling Nexus, a proprietary technology platform designed to streamline oncology workflows by unifying clinical decision support, evidence-based pathways and prior authorization into a single digital system.
The platform aims to improve NCCN guideline compliance and reduce delays and errors linked to fragmented authorization processes. According to Starling Oncology, Starling Nexus connects utilization management with real-time decision support and will evolve into a hub integrating ancillary services such as pharmacy and clinical trials, supporting physicians, health plans and patients within its value-based cancer care model.
Starling Oncology (NASDAQ: STLN) reported second quarter 2026 revenue of $161.3 million, up 34.6% year over year, with gross profit rising 55.2% to $27.2 million. Net loss narrowed to $9.8 million, or $(0.08) per share, and Adjusted EBITDA turned positive at $0.2 million. Cash and cash equivalents reached $41.1 million at June 30, 2026.
According to the company, strong specialty pharmacy performance and growth in capitated lives supported results. Full-year 2026 guidance was raised to revenue of $650–$670 million and gross profit of $105–$110 million, with Adjusted EBITDA now expected at $2–$7 million. Starling also expects about $150 million in 2026 capitated revenue and projects its medical loss ratio at 80%–90% over the next twelve months.
Starling Oncology (Nasdaq: STLN), formerly The Oncology Institute ("TOI"), announced a corporate rebrand to “Starling Oncology, Inc.™.” The company’s common stock will begin trading on Nasdaq under the new ticker symbol STLN on August 4, 2026, replacing “TOI.” According to the company, the new name reflects its evolution into an integrated oncology platform, while patients, payers, and providers are expected to experience no changes to phone numbers, portals, or points of contact and no disruption to care during the transition.
The Oncology Institute (NASDAQ: TOI) will release its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 5:00 p.m. Eastern Time. Investors can access the call via domestic and international dial-in numbers or through a live webcast on the company’s investor relations website. A telephone replay and webcast replay will be available until 11:59 p.m. Eastern Time on August 20, 2026.
The Oncology Institute (NASDAQ: TOI) completed a strategic refinancing, repaying its $86 million senior secured convertible note with Deerfield Partners. The repayment used a new $75 million OrbiMed term loan maturing in 2031 plus about $11 million of cash, aiming to boost liquidity, flexibility, and extend debt maturities without raising equity.
The Oncology Institute (NASDAQ: TOI) announced that Chief Medical Officer Yale D. Podnos, MD, MPH, FACS, will speak at the APG Spring Conference on May 28, 2026, in San Diego.
He will join a panel on Engaging More Specialists in Value-Based Care, sharing oncology-focused insights on outcomes, costs, care quality, and patient safety.
The Oncology Institute (NASDAQ:TOI) announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the B. Riley Securities Institutional Investor Conference in Marina Del Rey, CA, on May 21, 2026.
A fireside chat is scheduled from 9:00–9:40 a.m. PT and will be available via webcast on the company’s investor relations website.